NOTE
🌱 created from: majestec-1
toxicity_in_majestec-1
| Parameter | Details |
|---|---|
| CRS Patients | 119 (72.1%) |
| Timing | after step-up and cycle 1 |
| Severity | Grade 1/2, 1 Grade 3 (resolved) |
| Discontinuation | None |
| Median Onset | 2 days (range: 1-6) |
| Median Duration | 2 days (range: 1-9) |
| Supportive Measures | 110 (66.7%) |
| Tocilizumab | 60 (36.4%) |
| Low-Flow Oxygen | 21 (12.7%) |
| Glucocorticoids | 14 (8.5%) |
| Vasopressor | 1 (0.6%) |